Views

CrossRef citations to date

Altmetric

Original Articles: Clinical

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Xing-Nong YeInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and ;Department of Hematology, The fourth Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China

Xin-Ping ZhouInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Ju-Ying WeiInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Gai-Xiang XuInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Ying LiInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Li-Ping MaoInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Jian HuangInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;Department of Hematology, The fourth Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China

Yan-Ling RenInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Chen MeiInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Jing-Han WangInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Yin-Jun LouInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Li-Ya MaInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Wen-Juan YuInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Li YeInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Li-Li XieInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Yin-Wan LuoInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Chao HuInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Lin-Mei NiuInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Min-Hua DouInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Jie JinInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Hong-Yan TongInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and Correspondence[email protected]

show all

Abstract

Decitabine (DAC) is commonly used for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Previous studies have indicated DAC sequentially combined with idarubicin was an effective treatment for myeloid neoplasms. Therefore, a clinical study was conducted of the sequential combination of DAC followed by low-dose idarubicin/cytarabine in high-risk myeloid neoplasms. A total of 30 patients with a diagnosis of high-risk MDS, AML evolving from MDS or relapsed/refractory AML were enrolled in the study. DAC was administered 20 mg/m² daily for 3 consecutive days. Idarubicin (3 mg/m²/day) was administered 24 h after the last administration of DAC for 5–7 consecutive days, combined with cytarabine (30 mg/m²/day) for 7–14 days. The overall complete remission rate was 66.67%. The results demonstrate that epigenetic priming with decitabine followed by low-dose idarubicin/ytarabine has an increased anti-leukemia effect compared to traditional chemotherapy in high-risk myeloid neoplasms.

Keywords:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Information for

Open access

Opportunities

Help and information

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature